Arrowhead Pharmaceuticals, Inc.
ARWR
$65.09
$0.010.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 256.47M | 27.77M | 542.71M | 2.50M | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 256.47M | 27.77M | 542.71M | 2.50M | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 256.47M | 27.77M | 542.71M | 2.50M | 0.00 |
| SG&A Expenses | 31.29M | 37.41M | 36.09M | 30.71M | 21.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 212.37M | 193.32M | 161.51M | 163.91M | 162.20M |
| Operating Income | 44.11M | -165.55M | 381.20M | -161.41M | -162.20M |
| Income Before Tax | 36.12M | -179.09M | 369.62M | -175.12M | -172.80M |
| Income Tax Expenses | 20.00M | -437.00K | 1.75M | 103.00K | 546.00K |
| Earnings from Continuing Operations | 16.12M | -178.65M | 367.86M | -175.22M | -173.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -39.87M | 3.41M | 2.58M | 2.13M | 2.81M |
| Net Income | -23.75M | -175.24M | 370.45M | -173.09M | -170.54M |
| EBIT | 44.11M | -165.55M | 381.20M | -161.41M | -162.20M |
| EBITDA | 50.49M | -159.33M | 387.29M | -156.18M | -157.18M |
| EPS Basic | -0.17 | -1.26 | 2.78 | -1.39 | -1.37 |
| Normalized Basic EPS | -0.13 | -0.78 | 1.75 | -0.86 | -0.85 |
| EPS Diluted | -0.17 | -1.26 | 2.75 | -1.39 | -1.37 |
| Normalized Diluted EPS | -0.13 | -0.78 | 1.74 | -0.86 | -0.85 |
| Average Basic Shares Outstanding | 137.88M | 139.04M | 133.36M | 124.85M | 124.36M |
| Average Diluted Shares Outstanding | 137.88M | 139.04M | 134.48M | 124.85M | 124.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |